Development of a stability-indicating HPLC method for simultaneous determination of olanzapine and fluoxetine in combined dosage forms

Journal of Chromatographic Science

Volumn 47, Issue 7, 2009, Pages 605-611

  Pathak, A ^a   Rajput, S J ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350180102     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/47.7.605     Document Type: Article

References (25)

1. B.R. Matthews. Regulatory aspects of stability testing in Europe. Drug Dev. Ind. Pharm. 25: 831-56 (1999).
2. V.R. Sinha, Monika, A. Trehan, M. Kumar, S. Singh, and J.R. Bhinge. Stress studies on acyclovir. J. Chromatogr. Sci. 45: 319-24 (2007).
3. International Conference on Harmonization. Stability testing of new drug substances and products. International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2003.
4. International Conference on Harmonization. Stability testing: Photostability testing of new drug substances and products. Inter-national Conference on Harmonization, IFPMA, Geneva, Switzer-land, 1996.
5. M.A. Saracino, O. Gandolfi, R.D. Olio, L.A.E. Kenndler, and M.A. Raggi. Determination of olanzapine in rat brain using liquid chro-matography with coulometric detection and a rapid solid-phase extraction procedure. J. Chromatogr. A 1122: 21-27(2006).
6. L. Labat, M. Deveaux, P. Dallet, and J.P. Dubost. Separation of new antidepressants and their metabolites by micellar electroki-netic capillary chromatography. J. Chromatogr. B 773(1): 17-23 (2002).
7. S.A. Corya, S.W. Andersen, H.C. Detke, L.S. Kelly, L.E. Campen, T.M. Sanger, D.J. Williamson, and S. Dube. Long-term antide-pressant efficacy and safety of olanzapine/fluoxetine combination. J. Clin. Psychiatry 64(11): 1349-56 (2003).
8. J.D. Matthews, K.A. Bottonari, L.M. Polania, D. Mischoulon, C.M. Dording, R. Irvin, and M. Fava. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analysis. J. Clin. Psychiatry 63(12): 1164-70 (2002).
9. M. Tohen, E. Vieta, J. Calabrese, T.A. Ketter, G. Sachs, and C. Bowden. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. Arch. Gen. Psychiatry 60: 1079-88 (2003).
10. M.A. Raggi, G. Casamenti, R. Mandrioli, G. Izzo, and E. Kenndler. Quantitation of olanzapine in tablets by HPLC, CZE, derivative spectrometry and linear voltammetry. J. Pharm. Biomed. Anal. 23(6): 973-81 (2000).
11. L.J. Dusci, L.P. Hackett, L.M. Fellows, and K.F. Ilett. Determination of olanzapine in plasma by high-performance liquid chromatog-raphy using ultraviolet absorbance detection. J. Chromatogr. B 773(2): 191-97 (2002).
12. D.W. Boulton, J.S. Markowitz, and C.L. Vane. A high-perfor- mance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. J. Chromatogr. B 759(2): 319-323 (2001).
13. J.T. Catlow, R.D. Barton, M. Clemens, T.A. Gillespie, M. Goodwin, and S.P. Swanson. Analysis of olanzapine in human plasma uti- lizing reversed-phase high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B 668(1): 85-90 (1995).
14. C.S. Torre, M.A. Martinez, and E. Almarza. Several psychiatric drugs in whole blood using capillary gas-liquid chromatography with nitrogen phosphorus detection: comparison of two solid phase extraction procedures. Forensic Sci. Int. 155(2): 193-04 (2005).
15. A. Lerena, P. Dorado, R. Berecz, A. Gonzalez, M.J. Norberto, A. Rubia, and M. Caceres. Determination of fluoxetine and nor-fluoxetine in human plasma by high-performance liquid chro-matography with ultraviolet detection in psychiatric patients. J. Chromatogr. B 783(1): 25-31 (2003).
16. A. Zarghi, A. Kebriaeezadeh, R. Ahmadkhaniha, M. Akhgari, and N. Rastkari. Selective liquid chromatographic method for deter- mination of fluoxetine in plasma. J. AOAC Int. 84(6): 1735-37 (2001).
17. M.T. Maya, C.R. Domingos, M.T. Guerreiro, and J.A. Morais. Determination of the antidepressant fluoxetine in human plasma by LC with UV detection. J. Pharm. Biomed. Anal. 23(6): 989-996 (2000).
18. M.A. Raggi, F. Bugamelli, G. Casamenti, R. Mandrioli, D.D. Ronchi, and V. Volterra. Analytical methods for the quality control of Prozac capsules. J. Pharm. Biomed. Anal. 18: 699-06 (1998).
19. B.A. Olsen, D.D. Wirth, and J.S. Larew. Determination of fluox-etine hydrochloride enantiomeric excess using high-performance liquid chromatography with chiral stationary phases. J. Pharm. Biomed. Anal. 17: 623-30 (1998).
20. S.H.Y. Wong, S.S. Dellafera, R. Fernandes, and H. Kranzler. Determination of fluoxetine hydrochloride enantiomeric excess using high-performance liquid chromatography with chiral stationary phases. J. Chromatogr. 499: 601-08 (1990).
21. A. Mohamed, M.M. Mabrouk, and F.A. El-Barbary. Liquid chro- matographic determination of fluoxetine. J. Pharm. Biomed. Anal. 30(3): 561-71 (2002).
22. V.B. Reddy, S.K. Reddy, J. Sreeramulu, and G.V. Kanumula. Simultaneous determination of olanzapine and fluoxetine by HPLC. Chromatographia 66: 111-14 (2007).
23. W.N. Kuhn-Velten. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J. Chromatogr. B 843(1): 100-13 (2006).
24. The United States Pharmacopeia, USP-24, NF-19, United States Pharmacopoeial Convention, INC, Rockville, MD, Asian Edition, 2000, pp. 2149-51.
25. K. Florey. Analytical Profiles of Drug Substances, vol. 19. Academic Press, INC, San Diego, CA 1990, pp. 193-19.